Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

No more hospital trips? video nutrition counseling tested for cancer weight loss

NCT ID NCT07606417

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal is to see if telemedicine works as well as standard care for helping patients maintain or gain weight, while saving them travel time and expense.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Telemedicine-delivered nutritional counseling (video calls via WhatsApp, Zoom, or Teams)
What this could lead to
If successful, this could show that remote nutrition counseling is a practical, cost-saving way to help cancer patients manage weight loss and improve quality of life without frequent hospital visits.
What could go wrong
This is a small pilot study (80 participants) in one hospital in Pakistan, so results may not apply broadly. The intervention is behavioral, not a drug, so benefits may be modest and depend on patient adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age and Consent Capacity * Age ≥18 years (adults of either biological sex or gender identity) * Able to understand study procedures and provide written informed consent independently or with assistance from legally authorized representative 2. Cancer Diagnosis * Histologically or cytologically confirmed solid tumor malignancy of any type, including but not limited to: * Lung cancer (non-small cell or small cell) * Breast cancer * Gastrointestinal cancers: gastric (stomach), colorectal, pancreatic, esophageal, hepatobiliary (liver, gallbladder, bile duct) * Head and neck cancers (oral cavity, pharynx, larynx, nasal cavity, salivary glands) * Gynecological cancers: cervical, ovarian, endometrial, vulvar, vaginal * Genitourinary cancers: prostate, bladder, renal (kidney), testicular * Other solid tumors: sarcomas, melanoma, thyroid, brain tumors * Any cancer stage eligible (Stage I, II, III, or IV) 3. Cancer Cachexia * Documented unintentional weight loss meeting at least one of the following criteria: * Weight loss ≥3% of body weight within the past 3 months, OR * Weight loss ≥5% of body weight within the past 6 months * Weight loss must be documented by medical records, patient self-report, or measurement at screening visit compared to documented previous weight 4. Active Cancer Treatment * Currently receiving active anti-cancer treatment, OR * Scheduled to begin active anti-cancer treatment within 2 weeks of enrollment * Eligible anti-cancer treatments include: * Chemotherapy (cytotoxic agents, any regimen) * Radiation therapy (external beam or brachytherapy) * Targeted molecular therapy (tyrosine kinase inhibitors, monoclonal antibodies) * Immunotherapy (checkpoint inhibitors, CAR-T cell therapy) * Hormonal therapy for hormone-sensitive cancers * Combination therapies * Patients receiving palliative/supportive care only (without active anti-cancer treatment) are excluded 5. Performance Status * Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2: * Grade 0: Fully active; able to carry on all pre-disease activities without restriction * Grade 1: Restricted in physically strenuous activity but ambulatory; able to carry out light or sedentary work (e.g., light housework, office work) * Grade 2: Ambulatory and capable of all self-care activities but unable to carry out any work activities; up and about \>50% of waking hours 6. Technology Access and Literacy * Access to a smartphone or tablet device with video calling capability (personal device or family member's device that participant can use) * Reliable internet connectivity available via at least one of: * Home Wi-Fi network * Mobile cellular data plan (3G, 4G, or 5G) * Access to public/community Wi-Fi * For telemedicine group: willingness and ability to participate in video consultations 7. Language * Able to communicate verbally in Urdu (national language of Pakistan) or English * Able to understand spoken instructions and questions * Literacy not required; illiterate participants eligible with assistance from family/witness for consent and questionnaires 8. Geography * Able to attend in-person assessments at King Edward Medical University/Mayo Hospital, Lahore, Pakistan at baseline (Week 0) and Week 12 * For telemedicine group: only 2 hospital visits required (Weeks 0 and 12) * For standard care group: able to attend 7 hospital visits (Weeks 0, 2, 4, 6, 8, 10, 12) 9. Commitment * Willing to participate in the study for the full 12-week duration * Willing to comply with study procedures including dietary assessments, questionnaires, blood tests, and nutritional counseling sessions Exclusion Criteria: * Inability to Eat Orally * Severe dysphagia (difficulty swallowing) requiring enteral nutrition support via: * Nasogastric tube feeding * Percutaneous endoscopic gastrostomy (PEG) tube * Jejunostomy tube * Complete bowel obstruction preventing oral intake * Total parenteral nutrition (TPN) as sole nutritional support * Note: Partial oral intake supplemented with enteral nutrition is eligible if patient can consume at least some food by mouth 2. Refractory Cachexia * ECOG Performance Status 3 or 4: * Grade 3: Capable of only limited self-care; confined to bed or chair \>50% of waking hours * Grade 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair * Active cachexia management deemed not clinically appropriate or futile by treating oncologist * Estimated life expectancy \<3 months per treating oncologist's assessment * Imminent end-of-life care or transition to hospice care 3. Uncontrolled Comorbid Conditions * Uncontrolled diabetes mellitus defined as: * Glycated hemoglobin (HbA1c) \>9% within past 3 months, OR * Frequent hypoglycemic or hyperglycemic episodes requiring emergency care * Rationale: Uncontrolled diabetes affects nutritional metabolism and requires specialized dietary management beyond scope of this intervention * End-stage renal disease requiring dialysis (hemodialysis or peritoneal dialysis) o Rationale: Dialysis patients require specialized renal diet with protein, fluid, potassium, and phosphorus restrictions that differ substantially from cancer cachexia nutritional recommendations * Severe heart failure, New York Heart Association (NYHA) Functional Class IV: * Symptoms at rest; any physical activity causes discomfort * Rationale: Severe cardiac cachexia has different pathophysiology and requires cardiology-directed nutritional management 4. Psychiatric or Cognitive Impairment * Active psychiatric illness that would preclude meaningful participation or informed consent, including: * Severe major depressive disorder with active suicidal ideation * Acute psychotic episode (schizophrenia, bipolar disorder with psychosis) * Severe anxiety disorder preventing participation in counseling sessions * Cognitive impairment preventing informed consent or ability to participate, including: * Advanced dementia (moderate to severe; unable to follow simple instructions) * Severe delirium (acute confusional state) * Significant brain metastases causing cognitive dysfunction * Note: Mild cognitive impairment or controlled psychiatric conditions with stable treatment are not exclusionary 5. Concurrent Study Participation * Currently enrolled in another interventional clinical trial testing nutritional interventions, dietary supplements, or appetite stimulants * Rationale: Concurrent nutritional interventions would confound outcome assessment * Note: Participation in observational studies, cancer treatment trials (chemotherapy, radiation), or non-nutritional supportive care trials is permitted 6. Pregnancy or Lactation * Pregnant women (confirmed by urine or serum pregnancy test if reproductive potential) * Breastfeeding/lactating women * Rationale: Pregnancy and lactation have substantially different and increased nutritional requirements that require specialized prenatal/postnatal nutritional counseling beyond the scope of cancer cachexia management in this protocol 7. Severe Food Allergies or Intolerances * Known severe allergy or intolerance to recommended nutritional supplements (oral nutrition supplements, protein powders, vitamins/minerals) for which no suitable alternatives are available in Pakistan * Note: Common food allergies (dairy, eggs, nuts) are not exclusionary as alternative food sources can be recommended 8. Logistical Barriers * Unable to attend baseline assessment visit (Week 0) at King Edward Medical University/Mayo Hospital, Lahore * Unable to attend final assessment visit (Week 12) at the hospital * For telemedicine group: Complete inability to access internet or use smartphone/tablet even with family assistance * No reliable means of contact (no phone number, no address) 9. Other * Enrolled in this study previously (re-enrollment not permitted) * Non-cancer-related causes of weight loss that would confound cachexia assessment: * Active eating disorder (anorexia nervosa, bulimia nervosa) requiring psychiatric treatment * Intentional weight loss through dieting for weight management * Hyperthyroidism causing unintentional weight loss (must be controlled before enrollment) * Active gastrointestinal infection (parasites, chronic diarrhea from infectious cause) * Any condition that, in the opinion of the principal investigator, would compromise patient safety, study integrity, or ability to complete study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cachexia; cancer; sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cachexia cancer neoplasm Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Radiotherapy and Medical Oncology, Mayo Hospital Lahore, 54000, Lahore, Pakistan.

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.